Elvis Pacelat

Elvis Paćelat outlines some lessons from big pharma as medical device manufacturers succumb to new reporting obligations.

However conservative and heavily regulated the drugs business, it too must transform itself to exploit digital opportunities - if only to ward off disruption, says Elvis Paćelat.

Elvis Pacela asks why the prospect of harmonized content is so challenging, and what can pharma companies learn from other sectors about more optimal, modern ways of working and sharing data?